
    
      The primary endpoint is 1-year local recurrence rate and disease-free survival. We planned to
      recruit 170 patients who diagnosed as perivascular hepatocellular carcinoma. The patients
      will be randomized into SBRT group and RFA group as 1:1 ratio.
    
  